大熊制药育儿假返岗率达96%并获ESG社会项A+

As the government announced the introduction of a "short-term parental leave system" that will provide parental leave benefits in one- to two-week increments starting August 20, moves within the pharmaceutical industry to overhaul internal systems aimed at preventing career disruption after parental leave are drawing attention.
According to the "2026 Sustainability Report" that Daewoong Pharmaceutical disclosed on the 30th of last month, the company's employee return-to-work rate after parental leave reached 96% as of 2024. The company explained that this was the result of operating a communication system between departments and the human resources team before and after leave, and linking it with an internal Career Development Program (CDP) to minimize career gaps.
Daewoong Pharmaceutical has maintained its qualification for more than 12 consecutive years since its first certification in 2008 in the family-friendly company certification review overseen by the Ministry of Gender Equality and Family, and was selected as a newly established "Family-Friendly Leading Company" this year. In this review, Daewoong Pharmaceutical recorded 95.7 out of a perfect score of 100, exceeding the overall average of 86.6, and received a perfect score particularly in the management leadership category. In 2022, it also earned the "Family-Friendly Top Company" title.
Within the company, actual performance cases have emerged through flexible work arrangements and career transition programs. Representative examples include employees switching roles from research to the new drug technology strategy field (C&D Strategy Team) through the internal CDP, or using flexible work arrangements after returning to introduce digital healthcare platforms to hospitals and clinics. In addition, customized exercise programs for employees returning after childbirth and a culture that does not ask the reason for leave are cited as factors driving the return-to-work rate.
Such investment in organizational culture has also led to improvements in external ESG evaluation metrics. Daewoong Pharmaceutical earned an A+ grade in the social (S) category in the 2025 ESG evaluation released by the Korea Institute of Corporate Governance and Sustainability (KCGS). This is a one-notch rise from the A grade in the previous year. During the same period, its integrated grade and environmental (E) grade also both rose to A grades.